Telix Pharmaceuticals (OTCMKTS:TLPPF) Trading Up 0.7% – Here’s What Happened

Telix Pharmaceuticals Limited (OTCMKTS:TLPPF)’s stock price rose 0.7% on Friday . The stock traded as high as $10.48 and last traded at $10.48. Approximately 800 shares changed hands during trading, a decline of 82% from the average session volume of 4,443 shares. The stock had previously closed at $10.41.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Tuesday, July 7th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $20.00.

Telix Pharmaceuticals Stock Up 0.7%

The firm’s 50 day moving average is $10.17 and its two-hundred day moving average is $9.03.

About Telix Pharmaceuticals

Telix Pharmaceuticals is a molecularly targeted radiopharmaceutical company specializing in the development and commercialisation of diagnostic and therapeutic products for oncology and rare diseases. The company leverages radioisotopes conjugated to disease-specific targeting agents, enabling precise imaging and treatment of cancerous lesions. Telix’s portfolio includes investigational imaging compounds, such as a gallium-68-labeled prostate cancer agent, alongside therapeutic candidates that deliver beta- or alpha-emitting isotopes directly to disease sites.

Telix’s lead diagnostic program focuses on positron emission tomography (PET) imaging for prostate cancer, designed to improve detection and staging accuracy.